Shares of Qiagen N.V. (NYSE:QGEN – Get Free Report) saw unusually-strong trading volume on Monday . Approximately 3,107,377 shares were traded during trading, an increase of 23% from the previous session’s volume of 2,521,901 shares.The stock last traded at $42.6950 and had previously closed at $44.07.
Analysts Set New Price Targets
A number of equities research analysts have issued reports on the stock. Barclays set a $40.00 price objective on shares of Qiagen and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Weiss Ratings raised shares of Qiagen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. Berenberg Bank set a $45.50 target price on Qiagen and gave the stock a “hold” rating in a research note on Tuesday, July 14th. TD Cowen reaffirmed a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $43.00 price target on shares of Qiagen in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $43.93.
View Our Latest Analysis on QGEN
Qiagen Stock Performance
Qiagen (NYSE:QGEN – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.47% and a net margin of 19.49%.The business had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. During the same quarter in the prior year, the business earned $0.60 earnings per share. Qiagen’s revenue for the quarter was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in QGEN. Boston Partners bought a new stake in Qiagen in the 3rd quarter valued at about $179,450,000. Norges Bank bought a new position in Qiagen during the fourth quarter worth about $166,500,000. Dimensional Fund Advisors LP bought a new position in Qiagen during the third quarter worth about $58,079,000. Price T Rowe Associates Inc. MD increased its stake in shares of Qiagen by 12.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock worth $379,072,000 after purchasing an additional 906,589 shares in the last quarter. Finally, Deutsche Bank AG raised its position in shares of Qiagen by 9.7% in the fourth quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock valued at $355,614,000 after purchasing an additional 697,342 shares during the period. Institutional investors own 70.00% of the company’s stock.
Qiagen Company Profile
Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.
The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.
Featured Articles
- Five stocks we like better than Qiagen
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
